Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)
China · Delayed Price · Currency is CNY 15.60
-0.19 (-1.20%)
Jun 2, 2026, 3:00 PM CST
SHA:603896 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 613.72 | 628.6 | 691.35 | 770.34 | 817.67 | 759.99 |
Other Revenue | 11.58 | 11.58 | 13.76 | 14.01 | 11.4 | 7.15 |
| 625.3 | 640.18 | 705.11 | 784.35 | 829.07 | 767.14 | |
Revenue Growth (YoY) | -5.27% | -9.21% | -10.10% | -5.39% | 8.07% | 20.61% |
Cost of Revenue | 139.05 | 136.55 | 140.02 | 135.53 | 129.21 | 126.37 |
Gross Profit | 486.26 | 503.63 | 565.1 | 648.82 | 699.86 | 640.76 |
Selling, General & Admin | 352.48 | 363.74 | 397.84 | 403.79 | 405.17 | 397.19 |
Research & Development | 51.71 | 51.64 | 48.41 | 49.68 | 47.82 | 50.82 |
Other Operating Expenses | 22.06 | 2.6 | -2.15 | -4.52 | 6.84 | 7.67 |
Operating Expenses | 426.11 | 417.36 | 443.73 | 447.73 | 461.41 | 456.47 |
Operating Income | 60.14 | 86.27 | 121.36 | 201.09 | 238.45 | 184.3 |
Interest Expense | -28.07 | -24.21 | -14.93 | -24.7 | -13.03 | -10.17 |
Interest & Investment Income | 18.45 | 19.14 | 36.84 | 51.77 | 29.99 | 31 |
Other Non Operating Income (Expenses) | -0.66 | -0.61 | -1.1 | -0.43 | -0.68 | -0.56 |
EBT Excluding Unusual Items | 49.86 | 80.59 | 142.18 | 227.72 | 254.73 | 204.57 |
Gain (Loss) on Sale of Investments | 8.11 | 7.78 | 4.63 | 0.27 | -1.26 | -12.33 |
Gain (Loss) on Sale of Assets | 0.63 | 0.41 | 8.95 | 0.17 | 0.07 | 0.03 |
Asset Writedown | -0.01 | -0.01 | -0.02 | -0.03 | -0.06 | -0 |
Other Unusual Items | 15.13 | 13.36 | 18.74 | 26.77 | 24.48 | 8.79 |
Pretax Income | 73.72 | 102.14 | 174.48 | 254.91 | 277.97 | 201.06 |
Income Tax Expense | 85.34 | 84.02 | 0.04 | 0.43 | 0.45 | 0.75 |
Earnings From Continuing Operations | -11.62 | 18.12 | 174.44 | 254.48 | 277.51 | 200.31 |
Minority Interest in Earnings | 0.06 | 0.05 | - | - | 0.27 | 0.52 |
Net Income | -11.56 | 18.17 | 174.44 | 254.48 | 277.78 | 200.83 |
Net Income to Common | -11.56 | 18.17 | 174.44 | 254.48 | 277.78 | 200.83 |
Net Income Growth | - | -89.58% | -31.45% | -8.39% | 38.32% | 32.37% |
Shares Outstanding (Basic) | 200 | 202 | 198 | 196 | 194 | 191 |
Shares Outstanding (Diluted) | 200 | 202 | 198 | 196 | 194 | 191 |
Shares Change (YoY) | 0.12% | 1.87% | 1.26% | 0.77% | 1.56% | 3.77% |
EPS (Basic) | -0.06 | 0.09 | 0.88 | 1.30 | 1.43 | 1.05 |
EPS (Diluted) | -0.06 | 0.09 | 0.88 | 1.30 | 1.43 | 1.05 |
EPS Growth | - | -89.77% | -32.31% | -9.09% | 36.19% | 27.57% |
Free Cash Flow | -65.87 | -45.15 | -292.1 | -99.48 | 158.68 | 135.07 |
Free Cash Flow Per Share | -0.33 | -0.22 | -1.47 | -0.51 | 0.82 | 0.71 |
Dividend Per Share | - | - | 0.270 | 0.390 | 0.440 | 0.311 |
Dividend Growth | - | - | -30.77% | -11.36% | 41.25% | 29.79% |
Gross Margin | 77.76% | 78.67% | 80.14% | 82.72% | 84.41% | 83.53% |
Operating Margin | 9.62% | 13.48% | 17.21% | 25.64% | 28.76% | 24.02% |
Profit Margin | -1.85% | 2.84% | 24.74% | 32.45% | 33.51% | 26.18% |
Free Cash Flow Margin | -10.53% | -7.05% | -41.43% | -12.68% | 19.14% | 17.61% |
EBITDA | 136.35 | 160.86 | 189.5 | 267.62 | 295.78 | 233.47 |
EBITDA Margin | 21.80% | 25.13% | 26.88% | 34.12% | 35.68% | 30.43% |
D&A For EBITDA | 76.2 | 74.59 | 68.14 | 66.53 | 57.33 | 49.17 |
EBIT | 60.14 | 86.27 | 121.36 | 201.09 | 238.45 | 184.3 |
EBIT Margin | 9.62% | 13.48% | 17.21% | 25.64% | 28.76% | 24.02% |
Effective Tax Rate | 115.76% | 82.26% | 0.03% | 0.17% | 0.16% | 0.37% |
Revenue as Reported | 625.3 | 640.18 | 705.11 | 784.35 | 829.07 | 767.14 |
Advertising Expenses | - | 149.35 | 190.63 | 201.21 | 201.3 | 198.54 |